Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent

Background. Long-term clinical outcomes after femoropopliteal (FP) stentmg with nitmol stems have not yet been clear. We investigated the mid-term efficacy of FP stenting with mtinol steins. Methods: This study was a multicenter retrospective study. From April 2004 to December 2008, 511 consecutive patients (639 limbs; mean age 71 7 years; 71% male) who underwent successful FP stenting with nitinol sterns for de novo lesions were retrospectively selected and analyzed in this multicenter study. All patients had a minimum follow-up of 6 months. Restenosis was defined as >2.4 of peak systolic velocity ratio by duplex or >50% stenosis by angiogram. Primary [latency was defined as treated vessels without restenoms and repeat revasculanzation. Secondary patency was defined as target vessels that become totally occluded and are reopened by repeat revascularizanon. Results: Sixty-one percent of the patients had diabetes, 76% were claudicant, and 20% were on hemodialysis. Mean lesion length was 151 75 mm. Mean follow-up period was 22 11 months. Primary patency was 79.8%, 66.7%, and 63.1%, and secondary pay was 90.4%, 87.3%, and 86.2% at 1, 3, and 5 years, respectively. During the follow-up period, 53 patients (10%) died. Of them, cardiovascular death was 38% and stent fracture had occurred in 14%. On multivariate analysis by Cox proportional hazard ratio, cilostazol administration (hazard ratio [Hill, 0.52;P < .0001), stem fracture (HR, 1.6; P = .03), hemodialysis (HR, 1.7; P = .01), and Trans Atlantic Inter-Society Consensus (TASC) II class C/D (HR, 2.4; P < .0001) were the independent predictors of primary paten after successful FP stoning. Conclusion: Clinical efficacy of nitinol stent implantation for FP disease was favorable for up to S years. (J Vase Surg 2010;52:608-15.)